INTRODUCTION {#s1}
============

Since novel drugs such as proteasome inhibitors and immunomodulatory agents were first introduced for the treatment of multiple myeloma, survival outcomes have significantly improved \[[@R1]--[@R3]\]. However, multiple myeloma still remains an incurable disorder because almost all patients relapse and become refractory to salvage treatments \[[@R4], [@R5]\]. As treatment outcome may be associated with cytogenetic abnormalities at diagnosis, patients with multiple genetic alterations might show worse prognosis than patients without them \[[@R6], [@R7]\]. Genetic alterations may accumulate during the development of myeloma from asymptomatic monoclonal gammopathy of undetermined significance because myeloma cases are preceded by an asymptomatic expansion of clonal plasma cells \[[@R8], [@R9]\]. Amyloid light-chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by deposition of amyloid fibrils derived from immunoglobulin light chains in various organs \[[@R10]\]. AL amyloidosis and multiple myeloma are theoretically same disease entity at the cellular level, and AL amyloidosis was reported to share genetic susceptibility with multiple myeloma \[[@R11]\]. The presence of small plasma cell clones in AL amyloidosis implies that these clones could become larger, leading to overt multiple myeloma over time \[[@R12]\]. Thus, patients with myeloma may have heterogeneous subclones, and the identification of genetic abnormalities with low frequency in these subclones could be helpful for a better understanding of each patient with myeloma. However, it is difficult to detect low frequency genetic alterations in small subclones by conventional molecular testing using malignant plasma cells from bone marrow. Genomic next generation sequencing (NGS) has allowed for a thorough exploration of the genetic alterations possible in myeloma \[[@R13], [@R14]\]. However, NGS is still not readily used in clinical practice because it is both a high cost and time-consuming process. Thus, the development of clinically applicable platforms revealing genomic alterations could help to improve a risk-adapted treatment strategy. Here, we performed a pilot study to evaluate the feasibility of a targeted gene sequencing panel consisting of 83 genes in myeloma and AL amyloidosis patients.

RESULTS {#s2}
=======

Characteristics of patients {#s2_1}
---------------------------

A total of 35 patients was enrolled in this study; the median age at diagnosis was 60 years (range: 31--85). Patients were classified into one of three groups according to the percentage of plasma cells and the presence of organ amyloidosis and osteolytic lesions: myeloma (*n* = 17), myeloma with AL amyloidosis (*n* = 6), and AL amyloidosis (*n* = 12). Thus, 17 patients who were diagnosed with myeloma had at least 10% malignant plasma cells in their bone marrow in conjunction with increased M protein in the serum and/or urine. With the exception of one patient, all myeloma only patients also had at least one sign or symptom related to myeloma such as renal dysfunction, anemia, or osteolytic bone lesion (Table [1](#T1){ref-type="table"}). In the remaining 18 patients, the presence of amyloid depositions in various organs such as heart, kidney and gastrointestinal tract was pathologically confirmed; thus, they were diagnosed with AL amyloidosis. Six of these patients had ≥ 30% plasma cells in their bone marrow aspirates or had osteolytic lesions diagnosed as myeloma coupled with AL amyloidosis (Table [2](#T2){ref-type="table"}). The clinical and laboratory characteristics of patients at diagnosis and their initial treatments and transplantations are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The most commonly used treatment regimens were thalidomide, dexamethasone with or without cyclophosphamide (*n* = 13), and bortezomib, melphalan and prednisone (*n* = 9). Bortezomib-containing treatment was used for patients ineligible for autologous stem cell transplant (ASCT), whereas thalidomide-containing treatment was done for patients eligible for ASCT. Thus, ASCT was done in 13 patients as a part of the induction treatment. At the time of analysis, 26 patients were alive, while nine patients died from myeloma (*n* = 4), AL amyloidosis (*n* = 2), or myeloma with AL amyloidosis (*n* = 3). The overall survival was not significantly different among the three groups (Figure [1A](#F1){ref-type="fig"}). When patients with AL amyloidosis were grouped together regardless of myeloma, the comparison of overall survival was not different either (Figure [1A](#F1){ref-type="fig"}).

###### Characteristics and outcomes of patients with myeloma

  No.   S/A    Type     Osteolytic lesion   Plasmacytoma   Hgb \< 10 g/dL   Ca \> 11.5 mg/dL   LDH increased   BM PC%   ISS   Induction treatment   Response to induction   ASCT     Survival status   OS (months)
  ----- ------ -------- ------------------- -------------- ---------------- ------------------ --------------- -------- ----- --------------------- ----------------------- -------- ----------------- -------------
  1     M/46   λ        Presence                                                                               70       I     VD                    PD                               Dead              23
  2     F/75   IgG, λ   Presence            Presence                                                           90       II    VMP                   PD                               Alive             21
  3     M/68   IgA, λ                                                                                          60       II    VMP                   CR                               Alive             18
  4     M/74   λ        Presence                           Presence         Presence                           100      III   VMP                   PD                               Alive             20
  5     M/76   IgG, κ                                                                                          10       I     None                  NA                               Alive             17
  6     F/48   IgG, κ   Presence            Presence       Presence                                            40       I     VAD                   PR                      Single   Alive             68
  7     F/31   IgG, κ   Presence            Presence                        Presence                           35       I     TD                    PD                      Tandem   Dead              14
  8     M/71   IgM, κ   Presence                                                                               60       I     VMP                   SD                               Alive             21
  9     M/51   IgG, κ   Presence                           Presence                                            23       II    TD                    CR                      Single   Dead              20
  10    M/42   IgG, λ                                                                                          50       II    TD                    VGPR                    Single   Alive             22
  11    F/85   IgG, κ                                      Presence                                            60       II    VMP                   SD                               Alive             23
  12    M/63   IgM, κ   Presence                                                                               50       I     TD                    PD                      Tandem   Alive             22
  13    F/68   κ                            Presence                                                           40       I     VMP                   CR                               Alive             22
  14    F/54   IgG, κ                                      Presence                            Presence        16       II    TD                    SD                      Single   Alive             33
  15    F/66   IgG, κ                                      Presence                                            50       II    CMP                   PD                               Alive             21
  16    M/77   IgG, λ                                      Presence                                            100      III   VMP                   VGPR                             Alive             20
  17    M/43   IgA, κ                                                                                          30       II    TCD                   PD                      Tandem   Dead              29

S: sex; A: age; Hgb: hemoglobin; LDH: lactate dehydrogenase; BM: bone marrow; PC: plasma cell; DSS: ISS: International staging system; ASCT: autologous stem cell transplantation; OS: overall survival; VD; bortezomib, dexamethasone; VMP: bortezomib, melphalan, prednisone; VAD: vincristine, adriamycin, dexamethasone; TD: thalidomide, dexamethasone; CMP: carfilzomib, melphalan, prednisone; TCD: thalidomide, cyclophosphamide, dexamethasone; CR: complete response; VGPR: very good partial response; PR: partial response; SD: stable disease; PD: progressive disease.

###### Characteristics and outcomes of patients with AL amyloidosis including myeloma with amyloidosis

  No.   S/A    Type     Osteolytic lesion   Involved organ         Hgb \< 10 g/dL   LDH increased   BM PC%   ISS   Combined with MM   Induction treatment   Response to induction   ASCT     Survival status   OS (months)
  ----- ------ -------- ------------------- ---------------------- ---------------- --------------- -------- ----- ------------------ --------------------- ----------------------- -------- ----------------- -------------
  18    M/37   κ                            Heart, GI tract        Presence                         30       II    Yes                TCD                   PR                      Single   Alive             40
  19    M/62   IgG, κ   Presence            Kidney                 Presence         Presence        100      II    Yes                None                  NA                               Dead              1
  20    M/57   κ                            Liver                                                   30       II    Yes                TCD                   CR                      Single   Alive             34
  21    M/57   κ                            Heart                                                   30       II    Yes                MD                    PD                               Dead              4
  22    F/49   κ                            Liver                                                   50       II    Yes                TD                    CR                      Single   Alive             30
  23    M/71   IgG, κ   Presence            Heart                                   Presence        20       III   Yes                MD                    CR                               Dead              27
  24    F/67   IgG, κ                       Kidney                                                  20             No                 MD                    CR                               Alive             21
  25    F/59   λ                            Heart                                                   15             No                 VMP                   CR                               Alive             36
  26    F/55   κ                            Lung                                    Presence        15             No                 TD                    PR                      Single   Alive             28
  27    M/60   λ                            GI tract, Nerve                                         5              No                 None                  NA                               Alive             26
  28    F/47   IgG, λ                       Kidney, Heart, Nerve                                    20             No                 MD                    PD                               Dead              3
  29    M/77   IgG, λ                       Heart                                   Presence        15             No                 None                  NA                               Dead              3
  30    M/60   κ                            Liver, nerve                                            15             No                 TD                    PR                               Alive             14
  31    M/57   λ                            Heart, nerve                                            12             No                 TD                    SD                               Alive             20
  32    F/64   IgA, λ                       Kidney, Heart, Nerve                                    15             No                 MD                    PR                               Alive             19
  33    M/43   IgG, λ                       Kidney                                                  4              No                 None                  CR                      Single   Alive             17
  34    M/64   λ                            Kidney, Soft tissue                                     15             No                 TD                    PR                      Single   Alive             17
  35    M/77   IgA, λ                       Kidney, Heart, Nerve                                    20             No                 VMP                   SD                               Alive             17

S: sex; A: age; Hgb: hemoglobin; LDH: lactate dehydrogenase; BM: bone marrow; PC: plasma cell; DSS: Durie-Salmon stage; ISS: International staging system; ASCT: autologous stem cell transplantation; OS: overall survival; GI tract: gastrointestinal tract; TCD: thalidomide, cyclophosphamide, dexamethasone; MD: melphalan, dexamethasone; TD: thalidomide, dexamethasone; VMP: bortezomib, melphalan, prednisone; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NA: not applicable; MM: multiple myeloma.

![Survival plots for multiple myeloma patients with or without amyloidosis\
(**A**) Survival outcome of patients in different groups (**B**) *NRAS, KRAS*, and *BRAF* (MAPK pathway) mutation profile in multiple myeloma and AL amyloidosis patients](oncotarget-07-68350-g001){#F1}

Mutations in myeloma and AL amyloidosis {#s2_2}
---------------------------------------

Patients were genotyped using high depth panel sequencing with a mean depth of coverage, 846× ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Mutation analysis of all myeloma patients including the six patients with AL amyloidosis revealed NRAS as the most commonly mutated gene (30%, 7/23), followed by KRAS (26%, 6/23) and BRAF (22%, 5/23) (Figure [1B](#F1){ref-type="fig"}). One patient (patient \#1, Table [3](#T3){ref-type="table"}) showed multiple mutations in NRAS, KRAS, and BRAF, and two other patients (patients \#2 and \#23, Table [3](#T3){ref-type="table"}) showed BRAF mutations with either NRAS or KRAS. Three patients showed multi-site mutations in the KRAS or BRAF gene (patients \#6, \#7, and \#10, Table [3](#T3){ref-type="table"}). However, no significant mutations were found in the 12 patients with AL amyloidosis alone, although mutations were found in myeloma with AL amyloidosis (Figure [1B](#F1){ref-type="fig"}). Although some patients showed more than 30% allele frequency, the majority of mutations in the three genes showed low variant allele fractions (around 5%). Mutations in BRAF and KRAS were verified using droplet digital PCR (ddPCR), and the values of allele frequency from the 7 patients harboring low allele fraction (≤ 10%) mutations were highly correlated with those of ddPCR (*r* = 0.95) (Figure [2](#F2){ref-type="fig"}). Thus, the application of a targeted gene sequencing panel in myeloma patients identified mutations in mitogen activated protein kinase (MAPK) pathway-related genes (KRAS, NRAS, and BRAF). Interestingly, the low allele frequency mutations were detected in separate sequence reads from those with high allele frequency mutations ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}), demonstrating the ongoing alteration of MAPK pathway for the wild type tumor populations. These data suggest that the high sensitivity of our panel sequencing platform could allow for early detection of subclones with clinical significance.

###### Amino acid changes and allele frequencies of three genes (KRAS, NRAS, and BRAF) in co-occurrence samples

  Sample   Amino acid change (variant allele frequency, %)               
  -------- ------------------------------------------------- ----------- -----------
           G12A(1)                                                       
  \#1      G13R(14)                                          Q61R(3)     D594N(5)
           Q61K(2)                                                       
  \#2      Q61L(18)                                                      D594G(4)
  \#23                                                       G12A(2)     D594N(7)
           A146V(5)                                          V600E(4)    
  \#6                                                        G12C(1)     
           G13D(28)                                                      
  \#7                                                        G13D(56)    
           L19F(3)                                                       
  \#10                                                                   V600E(34)
                                                             I714V(33)   

![High correlation of VAF from cancer panel and digital droplet PCR\
(**A**) VAF from cancer panel and ddPCR (**B**) Scatter plot for VAF of cancer panel and ddPCR.](oncotarget-07-68350-g002){#F2}

Copy number variations in myeloma and AL amyloidosis {#s2_3}
----------------------------------------------------

In addition to mutational analysis, gene panel sequencing was used to detect chromosomal copy number variations (CNV), which are often associated with prognosis in myeloma patients. Three types of CNV were detected in myeloma patients in a mutually exclusive manner, while amyloidosis patients had scarcely any changes (Figure [3A](#F3){ref-type="fig"}). The three CNVs in myeloma patients were amplification of chromosome 1q, amplification of odd number chromosomes (hyperdiploidy), and deletion of chromosome 13q. In particular, the chromosome 13q deletion was frequently detected in patients with the dual diagnosis of myeloma and amyloidosis (5 out of 6). Notably, chromosome 1q amplification and 13q deletion are associated with poor prognosis in multiple myeloma \[[@R15], [@R16]\]. The CNV calls made from gene panel sequencing showed a significant correlation with those from the whole exome sequencing ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}), and a lower positive correlation with those from fluorescence *in situ* hybridization (FISH) data using a single probe (Figure [3B, 3C](#F3){ref-type="fig"}).

![Copy number variations estimated from gene panel sequencing\
(**A**) Pearson\'s correlation distances were used for the average-linkage hierarchical clustering of patients. Correlation analysis between the CNV estimation and FISH analysis for (**B**) chromosome 1q amplification and (**C**) chromosome 13q deletion.](oncotarget-07-68350-g003){#F3}

Association of treatment response and NRAS/KRAS/BRAF mutation {#s2_4}
-------------------------------------------------------------

Among the seven patients with NRAS mutation, four patients (patients \#1--4) were treated with bortezomib-containing treatment; three of these patients did not respond (Table [1](#T1){ref-type="table"}). Thus, 75% (3/4) of patients showed disease progression during bortezomib treatment, although the sample size was small. Two patients with BRAF mutations also failed to show response to bortezomib; however, these patients (patients \#1 and \#2) both had NRAS mutations. Although only two patients with KRAS mutations received the bortezomib-containing treatment (patient \#1, 8), neither responded to it. (One patient showed disease progression while the other maintained a stable disease state; Table [1](#T1){ref-type="table"}). There was no significant association between the presence of the mutation and the response to other drugs such as thalidomide (data not shown).

DISCUSSION {#s3}
==========

In this study, we identified mutations in three well-known oncogenes, KRAS, NRAS, and BRAF, in multiple myeloma patients. No mutations were found in patients with AL amyloidosis alone, although patients with myeloma combined with AL amyloidosis did show mutations in all three genes (Figure [1B](#F1){ref-type="fig"}). The frequency of the mutations in the three genes identified in our study was consistent with those presented in a recent study of whole-exome sequencing in 463 patients with myeloma enrolled in the National Cancer Research Institute Myeloma XI trial, which reported a dominant mutation in the RAS (43%) \[[@R17]\]. Mutations in RAS gene family have been reported to show predominant mutational activation of one member of the RAS gene family. Solid tumors such as colorectal and pancreatic cancers showed frequent KRAS mutations, whereas some hematologic cancers such as acute lymphoblastic leukemia predominately showed NRAS mutations \[[@R18]\]. Unlike other malignancies, mutations of KRAS and NRAS were found in approximately equal rates in myeloma \[[@R19], [@R20]\]. Similarly, the frequency of mutations was similar between NRAS (30%, 7/23) and KRAS (26%, 6/23) in our study (Figure [1B](#F1){ref-type="fig"}). BRAF mutations (22%, 5/23) were also found in five myeloma patients including two patients with both AL amyloidosis and myeloma (Figure [1B](#F1){ref-type="fig"}). The BRAF mutation is known to be mutually exclusive with KRAS and/or NRAS mutations in other cancers \[[@R21]\]; however, in our study, mutations in BRAF did not appear to be exclusive to either the KRAS or NRAS mutation because mutations in KRAS, NRAS, and BRAF were all found in the same patient (patient \#1, Table [3](#T3){ref-type="table"}). Given that each RAS family member can provide a similar oncogenic signal through the mitogen-activated protein kinase (MAPK) pathway promoting cell proliferation, the presence of these mutations could be expected to result in a worse treatment outcome than the absence of these mutations. Indeed, a previous study showed an association of NRAS mutations with a lower response rate to bortezomib and a shorter time to disease progression in bortezomib-treated patients \[[@R22]\]. In our study, patients with NRAS mutations showed poor response to bortezomib-containing treatments. Furthermore, the patient with mutation of three genes, KRAS, NRAS and BRAF (patient \#1, Table [3](#T3){ref-type="table"}) was primarily refractory to bortezomib, lenalidomide, and bendamustine-containing treatments. None of the mutations in the MAPK pathway-related genes were detected by conventional molecular tests at the time of initial diagnosis. Thus, a targeted sequencing such as our cancer panel may be useful for detecting low frequency genetic events, allowing for a predicted treatment response. As our patients with AL amyloidosis were mainly treated with thalidomide or alkylating agents, the association of the absence of the MAPK-pathway related gene mutations with the response to bortezomib could not be evaluated in this study (Table [2](#T2){ref-type="table"}). However, our previous study with AL amyloidosis patients showed that sixteen of nineteen (84%) patients who were treated with bortezomib, melphalan, and prednisolone had a hematologic response, including seven complete responders \[[@R23]\]. These results support the association of MAPK pathway gene mutations with the response to bortezomib.

Our pilot study applied a targeted gene sequencing panel consisting of 83 genes that were selected based on the availability of corresponding targeting agents. Thus, the genes used for the targeted sequencing could be targeted by developed anti-cancer drugs. Furthermore, gene panel sequencing provided large numbers of mutations as well as chromosomal amplifications or deletions with an important prognostic value compared to the conventional cytogenetic and FISH methods. As there are discrepancies between gene panel sequencing and conventional cytogenetic/FISH methods, further improvement is required for the use of next generation sequencing for cytogenetic analysis.

Compared to myeloma and myeloma with AL amyloidosis, the results of AL amyloidosis showed no evidence of major mutations. Indeed, the clinical features and treatment outcomes were mainly correlated with the type and extent of organ involvement rather than by the number of plasma cells in patients with AL amyloidosis \[[@R24], [@R25]\]. By comparison, a previous study with longitudinal whole genome sequencing of a high-risk myeloma patients demonstrated tumor heterogeneity at diagnosis and identified potential mutations contributing to myeloma development as well as transformation from myeloma to overt extramedullary disease \[[@R26]\]. Accordingly, genetic alterations could accumulate during the process of myeloma development and progression contributing to genetic heterogeneity of myeloma. This heterogeneity also might influence treatment outcomes of myeloma because certain clones with a given genetic mutations may be sensitive to one drug whereas a different clone having with a different genetic mutations may not respond to the drug, resulting in relapse or progression after treatment. Thus, the initial screening of the genetic mutation landscape for each myeloma patient at diagnosis may provide important information for subsequent treatment and follow-up of myeloma patients.

Nonetheless, our study has some limitations. First, our gene panel mainly consisted of genes covering targets of developed anti-cancer drugs. Given that the majority of targeted agents currently available focus on solid tumors, a substantial number of genes studied were related to solid tumor phenotypes rather than to myeloma. It is also possible that some patients had alterations in non-target regions. Second, we could not demonstrate an association of mutations in MAPK pathway-related genes (KRAS, NRAS and BRAF) with survival outcomes of our patients. Thus, further study with larger study populations and longer follow-ups are required to confirm the clinical utility of targeted sequencing. Recently, Kortum et al. investigated 72 untreated myeloma patients with deletion 17p using a myeloma-specific gene panel for targeted sequencing of 47 genes. They found a higher prevalence of TP53 mutation (28%) than previous studies and suggested that this targeted sequencing could provide a comprehensive insight into the mutational landscape of high-risk myeloma \[[@R27]\].

In conclusion, we present results of our pilot study with targeted genome sequencing for myeloma and AL amyloidosis. We believe that targeted gene panel sequencing will help to further improve myeloma diagnosis as well as track clonal heterogeneity. Furthermore, this diagnostic approach may provide more precise prognosis and better guidance for treatment decisions in myeloma patients.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

We enrolled consecutive patients who were diagnosed with multiple myeloma or AL amyloidosis at the Samsung Medical Center between 2013 and 2014. Patients were diagnosed with myeloma according to the presence of malignant plasma cells ≥ 10% of bone marrow aspirates and increased monoclonal proteins in serum and/or urine \[[@R28]\]. AL amyloidosis was diagnosed with the presence of amyloid deposits in involved organs, which was confirmed by Congo red staining and monoclonal protein in serum and/or urine. After obtaining informed consent from participating patients, we performed bone marrow aspiration. Plasma cells were isolated by magnetic separation using anti-CD138 microbeads and were stored at −80°C. The extent of disease in myeloma patients was determined using the International Staging System (ISS) consisting of serum albumin and beta-2 microglobulin \[[@R29]\]. All patients with myeloma received induction treatment with curative intent. Induction treatment was done with immunomodulatory agents or proteasome inhibitors according to the physicians\' discretion. After induction treatment, ASCT was done for eligible patients. To diagnose AL amyloidosis, patients receiving ASCT were \< 65 years with adequate cardiac function. However, patients ineligible for ASCT received only an alkylating agent containing a chemotherapeutic agent such as melphalan or dexamethasone. The hematologic response to treatment was based on the revised uniform response criteria by the International Myeloma Working Group \[[@R30]\]. The survival and disease statuses were updated at the time of analysis; thus, the last update was done in March, 2016. All aspects of the study were reviewed and approved by the Institutional Review Board (IRB) of the Samsung Medical Center (No. 2012-08-059).

Targeted sequencing {#s4_2}
-------------------

Targeted sequencing was done using a customized cancer panel. Genomic DNA was extracted from tissue specimens using QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). Genomic DNA quality and quantity were determined using a Nanodrop 8000 UV-Vis spectrometer (Thermo Scientific, Waltham, MA, USA), a Qubit 2.0 Fluorometer (Life Technologies Inc., Grand Island, NY, USA), and a 2200 TapeStation Instrument (Agilent Technologies, Santa Clara, CA, USA). Genomic DNA (250 ng) from each tissue was sheared with Covaris S220 (Covaris, Woburn, MA, USA) and was used for the construction of a library using probes and the SureSelect XT reagent kit, HSQ (Agilent Technologies) according to the manufacturer\'s protocol. As previously reported, this panel is designed to enrich exons of 83 genes covering 366.2 kb of the human genome \[[@R31]\]. After the enriched exome libraries were multiplexed, the libraries were sequenced using the HiSeq 2500 sequencing platform (Illumina, San Diego, CA, USA). Briefly, a paired-end DNA sequencing library was prepared through gDNA shearing, end-repair, A-tailing, paired-end adaptor ligation, and amplification. After hybridization of the library with bait sequences for 27 hr, the captured library was purified and amplified with an index barcode tag, and the library\'s quality and quantity were measured. Sequencing of the exome library was carried out using the 100 bp paired-end mode of the TruSeq Rapid PE Cluster kit and the TruSeq Rapid SBS kit (Illumina).

Variant detection {#s4_3}
-----------------

Sequence reads were mapped to the human genome (hg19) using the Burrows-Wheeler Aligner (BWA) \[[@R32]\]. Duplicate read removal was done using Picard (v1.93) and Samtools \[[@R33]\]. Local alignment was optimized using The Genome Analysis Toolkit (GATK) \[[@R34]\]. Variant calling was done only in targeted regions of the cancer panel. To detect single nucleotide variants, we integrated results of three kinds of variants caller \[[@R35]--[@R37]\], which increased sensitivity. We used a Pindel to detect insertions and deletions \[[@R38]\]. Copy number variations were calculated for targeted regions by dividing read-depth per exon by the estimated normal reads per exon using an in-house reference. Gene fusions in the target region were identified using an in-house algorithm.

Digital droplet PCR {#s4_4}
-------------------

Digital droplet PCR was performed on a QX200 ddPCR™ System (Bio-Rad, Hercules, CA, USA) platform. Briefly, ddPCR™ reaction mixes were prepared with template gDNAs, ddPCR™ Supermix (Bio-Rad), and TaqMan primer-probe mixtures and were partitioned into oil droplets (∼20,000) generated by a QX200 droplet generator. The droplets were then thermal-cycled under the same condition described above using Veriti 96-Well Thermal Cycler (Life Technologies). Amplified droplets were imaged on a QX200 droplet reader (Bio-Rad) and analyzed by QuantaSoft™ software (Bio-Rad). The concentration of nucleic acid sequence targeted by the FAM and VIC or FAM and HEX dye labeled probes was estimated by Poisson distribution.

Statistical analysis {#s4_5}
--------------------

The Kaplan--Meier method was used for univariate analysis of survival outcomes. Survival outcomes were compared with the log-rank test. Overall survival was measured from the date of diagnosis to the date of death due to any cause and was censored at the date of the last follow-up visit. A two-sided *P value* \< 0.05 was considered statistically significant.
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